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Introduction: The aim of this study was to examine the effect of lornoxicam used in preemp-
tive analgesia on the intensity of pain and requirement for analgesics in the perioperative
period for major abdominal surgery.
Methods: Sixty patients scheduled for elective major abdominal surgery were randomly
assigned to three groups after ethics committee approval. Patients in Group PRE (n¼ 20) re-
ceived lornoxicam i.v. 8 mg 20 min before incision and saline i.v. after skin closure; patients
in Group POST (n¼ 20) received saline i.v. 20 mins before incision and lornoxicam i.v. 8 mg
after skin closure; patients in Group C (n¼ 20) received saline i.v. 5 min before incision and
after skin closure. A standardized general anesthetic was used. All patients were started on
i.v. tramadol patient-controlled analgesia during the postoperative period. Pain intensity
was measured using the visual analog scale (VAS), and tramadol consumption. In addition,
the incidences of side effects were recorded at the end of the study period.
Results: There were no significant differences among the three groups of the demographic
data. Groups PRE and POST demonstrated significantly reduced pain scores compared
to Group C at various points in time. Group PRE also demonstrated a weakly significant
reduction in analgesic consumption of tramadol postoperatively compared to Groups
POST and C.
Conclusion: Lornoxicam administered preemptively appears to improve the quality of post-
operative analgesia and leads to reduced consumption of tramadol postoperatively in
patients undergoing major abdominal operations.
ª 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction patient to allow early mobilization, early enteral nutrition, ed-The use of a single analgesic to treat moderate to severe post-
operative pain has proved inadequate to ensure optimal anal-
gesia. Multimodal analgesia is currently recommended for
effective postoperative pain control.1 Principles of a multi-
modal strategy include control of postoperative pain of theA Congress, Greece, 2004
901.
om (A. Gurkan).
al Associates Ltd. Publishucation, and attenuation of the perioperative stress response
through the use of a combination of analgesic agents.1,2
Amultimodal strategy to control postoperative pathophys-
iology and facilitate rehabilitation results in accelerated
recovery and decreased length of hospitalization.3 Patients
undergoing major abdominal procedures and who participate.
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metabolic stress, preservation of total-body protein, shorter
times to extubation, lower pain scores, earlier return of bowel
function, and earlier fulfillment of intensive care unit dis-
charge criteria.2 The multimodal approach may even reduce
the length of hospitalization for patients undergoing colon re-
section from a median of 6–10 days to 2 days.4 This approach
may decrease perioperative morbidity, and improve patient
satisfaction without compromising safety.
Preemptive analgesia is one of the components for multi-
modal strategy. The concept of preemptive analgesia consists
of an antinociceptive treatment that prevents central neural
sensitization that amplifies postoperative pain. This implies
that the treatment has been established when the noxious
stimulus starts.2 Non-steroidal anti-inflammatory drugs
(NSAIDs) are commonly administered as adjuvants during
the preoperative period because of their ability to improve
the control of postoperative pain while reducing the need for
opioid analgesics.1 However, the possible preemptive analge-
sic effect of NSAIDs is currently being debated.
Lornoxicam is a relatively new thienothiazine derivative of
the oxicam class of NSAIDs. In animal studies, lornoxicamhas
demonstrated cylo-oxygenase inhibitory activity approxi-
mately 100 timesmore powerful than that of tenoxicam, along
with analgesic activity approximately 10 times greater than
that of either tenoxicam or piroxicam.5 Additionally, and in
contrast to other oxicams, lornoxicam has a short plasma
half-life of approximately 4–6 h. This may translate into a bet-
ter tolerability profile for lornoxicam, since NSAIDs with long
plasma half-lives have been associated with a higher inci-
dence of adverse effects.5
In the present study, we tried to assess the effect of intra-
venous lornoxicam administered before incision or after inci-
sion on tramadol consumption in the postoperative period.2. Methods
The study protocol was approved by the hospital Ethics Com-
mittee, and a written informed consent was obtained from all
patients before the study. The study included 60 adult patients
undergoing major abdominal surgery (upper or upper and
lower medial laparotomy) and treated postoperatively in the
surgical intensive care unit. Exclusion criteria were as follows:
preoperative use of analgesics, allergy to NSAIDs, history of
peptic ulcer disease, coagulopathy, or renal dysfunction. Sixty
patients were randomly assigned to three groups.
On arrival at the preanesthetic room, standard monitoring
equipment consisting of electrocardiography, noninvasive
blood pressure monitoring, and pulse oximetry was installed.
Patients in Group PRE (n¼ 20) received lornoxicam (Nycomed
GmbH, Austria) i.v. 8 mg 20 min before incision and saline
i.v. after skin closure; patients in Group POST (n¼ 20) received
saline i.v. 20 min before incision and lornoxicam i.v. 8 mg after
skin closure; patients in Group C (n¼ 20) received saline i.v.
five minutes before incision and after skin closure. All medi-
cineswere prepared by a nursewho had no other involvement
in the study. None of the patients andmanaging anaesthetists
was aware of the randomization code. One day before the
operation, patients received instructions about the use ofa patient-controlled analgesia (PCA) device (APM, Abbott
Laboratories, North Chicago, IL) and the visual analog
scale (VAS; 0¼ ‘‘no pain’’ and 10¼ ‘‘worst pain imaginable’’)
for pain.
A standardized general anestheticwas used. Inductionwas
achievedwith 10 mg/kg atropine, 1 mg/kg remifentanil, 2 mg/kg
propofol. Atracurium (0.5 mg/kg) was given to facilitate oro-
tracheal intubation. Maintenance of anesthesia consisted of
desflurane 4–6% (end-tidal) and 60% nitrous oxide in oxygen.
Remifentanil infusion was started at an initial rate of 0.5 mg/
kg/min. After intubation, remifentanil infusion rate was re-
duced by 50%. At the completion of skin closure,muscle relax-
ation was reversed and patients extubated.
After tracheal extubation, patients were transferred to the
PACU. Postoperative pain was assessed using a visual analog
scale. Postoperative analgesia was provided by i.v. PCA trama-
dol (Salutas Pharma GmbH, Germany). Patients were con-
nected to the PCA-device on arrival in the PACU. The PCA
solution contained tramadol 3 mg/mL. The administration
variables were as follows: initial dose, 50 mg; demand dose,
20 mg; lockout interval, 10 min; 4-h limit, 300 mg; and no basal
infusion. Pain was assessed using VAS (at rest, on exertion) at
1 h, 2 h, 4 h, 12 h, and 24 h after surgery. Patients were given
additional analgesic (lornoxicam 8mg i.m.) when analgesia
was inadequate (VAS> 3). Total and incremental tramadol
consumption at these times was also recorded from the
PCA-device. Patients were evaluated for the presence of ad-
verse events such as nausea, vomiting, dizziness, drowsiness,
sedation, anxiety, dyspepsia, indigestion. Nausea was evalu-
ated using a two point scale; 0¼ absent, 1¼ positive. Metoclo-
pramide was given in the case of vomiting or after two
successive episodes of nausea. The degree of sedation was
rated on a four-point scale; 0¼ awake, 1¼ drowsy, 2¼ asleep
but rousable, 3¼ unrousable. All measurements were
recorded by the same anesthesia resident who was blinded
to the study drugs administered. At the end of the study, pa-
tient satisfaction was questioned (excellent, good, fair, poor).
The postoperative tramadol consumption was used as the
main criterion for statistical analysis. We calculated that 15
patients in each group would be necessary for the assess-
ment of a 20% decrease in tramadol consumption for treat-
ment groups with a Type 1 error value of 0.05 and power
of the study 80%. Demographic characteristics were analyzed
using Student’s t-test, while the VAS pain scores and PCA
tramadol usage were analyzed using Fisher’s exact test.
The Chi-square test was used to analyse the frequency of
nausea, vomiting or pruritus. Statistically testing was per-
formed using SPSS 10.0 program for Windows (SPSS Inc.,
Chicago, IL), with a P value <0.05 considered statistically
significant.3. Results
The demographic characteristics were similar, and there were
no significant differences with respect to duration of surgery
(Table 1).The VAS scores were significantly higher in the con-
trol group compared with the Group PRE and Group POST at
1 h, 2 h, 4 h, and 12 h after surgery (P< 0.05) (Tables 2 and 3).
The VAS scores at 1 h, 2 h, 4 h, and 12 h in Group PRE were








Age (yr) 54.8 8.6 48.5 12.1 50.4 11.3
Weight (kg) 67.6 14.8 61.9 12.3 70 18.2




10 (50%) 12 (60%) 12 (60%)




4 (20%) 3 (15%) 2 (10%)
Gender (F/M %) 45/55 40/60 50/50
Data are presented as mean SD. There were no significant differ-
ences among the three groups.







Group C (n¼ 20)
1 5.4 4.1 5.9 3.8 8.1 4.7*
2 4.0 2.3 5.1 3.2f 6.8 3.9*
4 3.8 2.1 3.9 2.5 5.4 1.9*
12 3.7 2.5 3.2 2.1 5.1 1.7*
24 2.8 2.1 2.8 2.3 3.9 1.6
Data are presented as mean SD.
*: P< 0.05, versus Group PRE and POST.
f: P< 0.05, versus Group PRE.
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VAS scores at 2 h (P> 0.05) (Tables 2 and 3). Tramadol con-
sumption in Group PRE and Group POSTwas lower than Group
C (P< 0.05) (Table 4). Although tramadol consumption was de-
termined to be lower in Group PRE than Group POST in all
measuring time, there was no significant difference in total
tramadol consumption between.
Adverse events observed during the study and patient sat-
isfaction are summarized in Tables 5 and 6. In total, 39 adverse
events were reported by 26 (43.3%) patients. The most com-
monly reported adverse events in all three groups were vom-
iting and nausea. All adverse events were mild to moderate in
intensity; most were transient. No severe or serious adverse
events were reported. There were no significant differences
in the incidence of adverse events (P> 0.05).4. Discussion
The authors of studies on the preemptive analgesic effects of
NSAIDs have reported contradictory results, although its
clinical and experimental existence has been established.6,7
Lornoxicam is a NSAID that blocks constitutive cyclooxyge-
nase (COX-1) and inducible cyclooxygenase (COX-2) and con-
sequently inhibits the production of prostaglandins and









1 4.3 3.1 5.2 3.2 7.7 3.1*
2 2.9 3.2 4.3 2.1f 6.3 3.1*
4 2.8 2.8 3.1 2.7 5.2 2.2*
12 2.3 2.1 2.1 2.2 4.7 1.8*
24 2.0 2 2.2 2.1 2.6 1.2
Data are presented as mean SD.
*: P< 0.05, versus Group PRE and POST.
f: P< 0.05, versus Group PRE.antinociceptive and anti-inflammatory action of NSAIDs
may be related to the inhibition of nitric oxide synthase acti-
vation, reduced production of pro-inflammatory cytokines
(through their inhibitory action on the nuclear factor NF-kB)
and lipoxine activation (endogenous anti-inflammatorymedi-
ators).10 Consequently, the multidirectional action of NSAIDs
suggests that theremay be a possibility of modifying the noci-
ception process by the use of these drugs to induce preemp-
tive analgesia in the perioperative period.
Our results demonstrate that preoperative single dose lor-
noxicam reduced VAS pain scores and tramadol consump-
tion. A similar benefit has been previously demonstrated
by combining NSAIDs with opioids, where the addition of
these analgesics reduced the consumption of opioids.5,9–11
It has been demonstrated that lornoxicam improves the
quality of postoperative analgesia and leads to reduced con-
sumption of opioid analgesics.11 Ilias and Jansen,5 reported
that preoperative administration of lornoxicam 8 mg pro-
duces equaanalgesic effect to tramadol 50 mg and is better
tolerated.
Nausea and vomiting have been reported in previous stud-
ies with lornoxicam.5,11 However, a number of other factors
have been shown to contribute to these events, including
the administration of anesthetic agents, surgical procedure
and anesthetic techniques, hypotension, and a previous his-
tory of postoperative nausea and motion sickness.5 Also, the
administration of opioids with a PCA system can aggravate
postoperative nausea and vomiting. In the present study, al-










1 75.3 12.3 84.7 18.1 109.9 19.6*
2 48.5 5.3 58.9 7.6 68.8 7.3*
4 69.8 8.7 72.1 10.7 88.9 11.7*
12 99.6 21.9 108.5 26.6 133.2 17.4*
24 137.8 38.3 145.6 39.6 165.8 36.7*
Total 428.1 48.9 467.1 47.3 561.7 41.4*
Values are mean SD (mg).
PCA¼ patient-controlled analgesia.
*P< 0.05 compared Group PRE and POST.







Nausea 6 (30%) 5 (25%) 8 (40%)
Vomiting 2 (10%) 1 (5%) 3 (15%)
Dyspepsia – 1 (5%) –
Antiemetic rescue 2 (10%) 2 (10%) 4 (20%)
Headache 1 (5%) 1 (5%) 3 (5%)
Values are number (n) and percentages (%). No significant differ-
ences were found between the groups.
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significant. It should be noted the preoperative administration
of lornoxicam was accompanied by a lower incidence of nau-
sea and vomiting,whichwas probably linked to the lower con-
sumption of tramadol and better pain control.
It is known that NSAIDs inhibit biosynthesis of thrombox-
ane A2. The reduced production of thromboxane A2 prevents
platelet aggregation and may increase blood loss during and
after surgery. NSAIDs decrease platelet aggregation and in-
crease bleeding time and thus may increase perioperative
and postoperative bleeding.12 Rogers et al.13 found that intra-
operative median blood loss in patients receiving ketorolac
before laparoscopic gynaecological surgery exceeded that of
patients who received it after surgery. In their study of the an-
algesic efficacy of diclofenac after major abdominal surgery,
Hodsman et al.14 report on two diclofenac group patients sub-
mitted to abdominoperitoneal resection of the rectum with
extensive pelvic dissection. Both patients developed postoper-
ative bleeding and required reoperation. However, studies us-
ing lornoxicam and ketoprofen have not detected problems
with surgical bleeding, bleeding time, blood transfusions re-
quirements, or postoperative bleeding.5,11 In our study, there
was no case of excessive bleeding in the lornoxicam groups
during the postoperative period, and none of the patients
from either group required reoperation. Gastrointestinal com-
plications (gastritis, ulcer perforation and bleeding, dyspepsia,
indigestion) have been well described with the chronic use of
NSAIDs.15 However, the risk of serious gastrointestinal
adverse effects with NSAIDs is very low after short-term peri-
operative use. In this study, only one patient in the lornoxi-
cam preincisional group complained of dyspepsia.
In conclusion, lornoxicam administered preemptively ap-
pears to improve the quality of postoperative analgesia and
lead to reduced consumption of tramadol postoperatively in







Poor 0 0 4 (20%)
Fair 3 (15%) 4 (20%) 6 (30%)
Good 5 (25%) 7 (35%) 4 (20%)
Excellent 7 (35%) 4 (20%) 1 (5%)





The Local Ethical committee of Tepecik Hospital has approved
the study. The reference number is 2006/376. (Trial registry
number – ISRCTN: 2006/34).r e f e r e n c e s
1. Jin F, Chung F. Multimodal analgesia for postoperative pain
control. J Clin Anesth 2001;13:524–39.
2. Wu CL. Acute postoperative pain. In: Miller RD, editor. Miller’s
anesthesia. 6th ed. Philadelphia: Elsevier Churchill
Livingstone; 2005. p. 2729–62.
3. Kehlet H, Wilmore DW. Multimodal strategies to improve
surgical outcome. Am J Surg 2002;183:630–41.
4. Basse L, Raskov HH, Hjort Jakobsen D, Sonne E, Billesbolle P,
Hendel HW, et al. Accelerated postoperative recovery
programme after colonic resection body composition. Br J
Surg 2002;89:446–51.
5. Ilias W, Jansen M. Pain control after hysterectomy: an
observer blind, randomised trial of lornoxicam versus
tramadol. Br J Clin Pract 1996;50:197–202.
6. Woolf CJ, Chong M. Pre-emptive analgesia treating
postoperative pain by preventing the establishment of central
sensitization. Anesth Analg 1993;77:362–79.
7. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of
central neuroplasticity to pathological pain: review of clinical
and experimental evidence. Pain 1993;52:259–85.
8. Rosenow DE, Albrechtsen M, Stolke D. A comparison of
patient-controlled analgesia with lornoxicam versus
morphine in patients undergoing lumbar disk surgery. Anesth
Analg 1998;86:1045–50.
9. Likar R, Krumpholz R, Pipam W, Sadjak A, Kapral S,
Forsthuber E, et al. Randomized, double-blind study with
ketoprofen in gynecologic patients. Preemptive analgesia
study following the Brevik–Stubhaug design. Anaesthetist
1998;47:303–10.
10. Wnek W, Zajacczkowska R, Wordliezek J, Dobrogowski J,
Korbut R. Influence of preoperative ketoprofen
administration (preemptive analgesia) on analgesic
requirement and the level of prostaglandins in the early
postoperative period. Pol J Pharmacol 2004;56:547–52.
11. Trampitsch E, Pipam W, Moertl M, Sadjak A, Dorn C, Sittl R,
et al. Preemptive randomized, double-blind study with
lornoxicam in gynecological surgery. Schemerz 2003;17:4–10.
12. Oberhofer D, Skok J, Nesek-Adam V. Intravenous ketoprofen
in postoperative pain treatment after major abdominal
surgery. World Surg 2005;29:446–9.
13. Rogers JE, Fleming BG, Macintosh KC, Jhonston B, Morgan-
Hughes JO. Effect of timing ketorolac tromethamine
on hemostasis in volunteers. Clin Pharmacol Ther 1988;43:
542–6.
14. Hodsman NB, Burns J, Blyth A, kenny GN, McArdle CS,
Rotman H. The morphine sparing effects of diclofenac
sodium following abdominal surgery. Anaesthesia 1987;42:
1005–8.
15. Aubrun F, Landeron O, Heitz D, Coriat P, Riou B. Randomized,
placebo-controlled study of the postoperative analgesic
effects of ketoprofen after spinal fusion surgery. Acta
Anaesthesiol Scand 2000;44:934–9.
